BioSpace News Archive

Biocept, Inc. (Nasdaq: BIOC) announces that it will release financial results for the three and 12 months ended December 31, 2021 and will file its Annual Report on Form 10-K with the Securities and Exchange Commission (SEC) on Thursday, March 31, 2022.

Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical stage biopharmaceutical company advancing oral therapies to aid patients suffering with acute and chronic gastrointestinal (GI) complications, today provides a business update and reports its financial results for the year ended December 31, 2021.

A study published in BMJ Open describes the Patient Journey as it relates to awareness, communication, and involvement with decision making during experiences with preeclampsia, a potentially life-threatening hypertensive disorder of pregnancy.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) announced today the launch of an Expanded Access Program (EAP) for AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO; also known as ursodoxicoltaurine]) in the U.S. for people living with amyotrophic lateral sclerosis (ALS) that meet program eligibility criteria.

Antengene Corporation Limited today announced its financial results for the full year ended December 31, 2021 and provided corporate updates on key events and achievements since the start of 2021.

Company Provides Update on Clinical Trial Design of Upcoming Phase 3 Clinical Trials in Parkinson’s Disease on March 20, 2022.

Orphan drugs are the novel class of pharmaceutical drugs which are indicated for the diagnosis, prevention, and treatment of rare medical disorders.

Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces that it received transparency notifications from the shareholders listed below, notifying the number of voting rights attached to shares mentioned next to their respective names in the table below.

Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announces it will release its year end 2021 financial results after the U.S. financial markets close on Wednesday, March 23, 2022.

Physicians report that they need to devote as many as 10 additional hours per workweek to charting, much of which is after hours, based on an additional 5-10 minutes per chart and a 20 patient per day workload.